Plasma MicroRNA Profiling Reveals Loss of Endothelial MiR-126 and Other MicroRNAs in Type 2 Diabetes

By A. Zampetaki, S. Kiechl, I. Drozdov, P. Willeit, U. Mayr, Marianna Prokopi, A. Mayr, Siegfried Weger, Friedrich Oberhollenzer, E. Bonora and 3 more. Circulation Research, 2010

1,448 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/4099ce1b7585d96dbbd798b3af164970f36416c5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. M. Hill
2. F. Paneni
3. Joshua A. Beckman
4. M. Creager
5. J. Sowers
6. Guanghong Jia
7. Ruth Nussinov
8. F. Cosentino

Citations in the corpus

• Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I (2013, background): “Plasma miR profiling showed a profound down-regulation of miR-126 in a cohort of diabetic patients.(67) Recent evidence suggest that reduced miR-126 expression levels are partially responsible for impaired vascular repair capacities in diabetes.”
• MicroRNA in Control of Gene Expression: An Overview of Nuclear Functions (2016, background): “Because of their ubiquitous role in gene regulation, they are involved in many physiological processes, such as differentiation, proliferation, apoptosis and development, and their dysregulation has been related to various pathological disorders, including muscular dystrophy [2], diabetes [3] and se”
• Adipose Tissue Macrophage-Derived Exosomal miRNAs Can Modulate In Vivo and In Vitro Insulin Sensitivity. (2017, unknown): “Previous reports have assessed blood miRNA content in normal, obese, or type 2 diabetic individuals (Iacomino et al., 2016; Ortega et al., 2014; Pescador et al., 2013; Zampetaki et al., 2010).”
• Structure and dynamics of molecular networks: A novel paradigm of drug discovery: A comprehensive review (2012, background): “As an additional extension of insulin signaling, recent studies started to uncover the changes and most influential members of the microRNA regulatory network in diabetes (Huang et al., 2010c; Zampetaki et al., 2010).”
• Extracellular miRNAs: From Biomarkers to Mediators of Physiology and Disease (2019, background): “Importantly, miR-223 is reduced in individuals up to 10 years prior to diagnosis of disease (Zampetaki et al., 2010) and is also reduced in obese patients (Wen et al.”
• Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity (2018, background): “miR15a, -21, -24, -29, -30d, -103, -126, -146a, -150, -191, -223, -320, -375, and -486 have all been reported to be increased in type 2 diabetic individuals.(142,143) In cardiac tissue of a type 1 diabetic rodent model, expression of miR-21, -24, -142-3p, -195, -199a-3p, -700, -705, -208, -221, and ”